Advertisement

Inpharma Weekly

, Volume 940, Issue 1, pp 9–9 | Cite as

Buying time with batimastat

new hope for cancer patients
  • Ian Mundell
Newsletter Article

Abstract

Batimastat represents a curious departure in anticancer therapy since it does not kill the cancer cells, but rather impedes their progress. Accordingly, it may have promise as a management tool that will buy time for other interventions. Phase I/II trials of the drug have shown that it is safe, and have also indicated efficacy in controlling cancer progression. Now, British Biotechnology and its collaborators are setting out to repeat the results on a larger scale. They also hope to elucidate the drug’s mechanism.

Keywords

Ovarian Cancer Malignant Ascites Batimastat Preclinical Work Phase IIII Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1994

Authors and Affiliations

  • Ian Mundell

There are no affiliations available

Personalised recommendations